Bioequivalence Study of Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Clinical trial NCT05085587 · UNKNOWN

Trial details

NCT number: NCT05085587
Sponsor: Respirent Pharmaceuticals Co Ltd.
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Bioequivalence Asthma

Start date: 2021-10-01
Primary completion: 2021-10-25
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.